AstraZeneca stock gains 0.03 percent pre-market to EUR 143.08
Published on 10/08/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock was EUR 143.08 in pre-market trading at Lang & Schwarz at 7:42 a.m. CEST on October 8, 2026. The shares were up 0.03 percent versus the prior close of EUR 143.03 at Lang & Schwarz on October 7, 2026, before the Xetra session.
Pre-market trading
The quoted bid was EUR 142.55 and the ask was EUR 143.60. Xetra trading was scheduled to begin at 9:00 a.m. CEST. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of AstraZeneca stock.
Recent company development
In a release dated October 5, 2026, AstraZeneca said it had completed a $2 billion equity investment in Summit Therapeutics. The company said the investment would accelerate development of ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in combination with antibody-drug conjugates across tumor types.
The same release said AstraZeneca and Summit had entered into a clinical collaboration to evaluate sonesitatug vedotin in combination with ivonescimab. AstraZeneca also said the companies intended to enter an additional agreement for a global development program combining other AstraZeneca cancer medicines with ivonescimab.
